Vertex (VRTX) director gets 2,866 fully vested stock options grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Vertex Pharmaceuticals director Michel Lagarde received a fully vested stock option grant as part of his compensation. On May 1, 2026, he was awarded options to acquire 2,866 shares of Vertex common stock at an exercise price of $424.45 per share. These options are already fully vested and expire on April 30, 2036, and represent a routine, non‑market transaction rather than an open‑market trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lagarde Michel

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	2,866	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 2,866 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 2,866 options Exercise price: $424.45 per share Post-grant derivative holdings: 2,866 options +1 more

4 metrics

Options granted 2,866 options Director stock option grant on May 1, 2026

Exercise price $424.45 per share Strike price for the 2,866 stock options

Post-grant derivative holdings 2,866 options Total stock options held after this transaction

Expiration date April 30, 2036 Stock option grant expiration

Key Terms

Stock Option (Right to Buy), Common Stock, Fully vested

3 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Fully vested financial

"Footnote states: "Fully vested.""

Form 4 Insider Transactions: What Each Field Means →

05/05/2026 - 05:06 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lagarde Michel

(Last)

(First)

(Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVE

(Street)

BOSTON

MASSACHUSETTS

02210

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$424.45	05/01/2026		A		2,866		⁽¹⁾	04/30/2036	Common Stock	2,866	$0	2,866	D

Explanation of Responses:

1. Fully vested.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Michel Lagarde report in this Vertex (VRTX) Form 4 filing?

Michel Lagarde reported a grant of stock options to buy 2,866 Vertex shares. The options were awarded at a $424.45 exercise price per share, are fully vested on grant, and give him direct rights to acquire common stock until their 2036 expiration.

Is Michel Lagarde’s Vertex (VRTX) stock option grant an open-market purchase?

No, this is a compensation-related stock option grant, not an open-market purchase. The Form 4 shows options awarded at a $424.45 exercise price with zero cost on grant, providing upside exposure without reflecting a cash share purchase in the market.

How many Vertex (VRTX) shares are covered by Michel Lagarde’s options?

The reported grant covers options on 2,866 shares of Vertex common stock. Each option allows Lagarde to buy one share at $424.45, giving him potential future ownership of 2,866 shares if he chooses to exercise before expiration.

When do Michel Lagarde’s Vertex (VRTX) stock options expire?

The stock options granted to Michel Lagarde expire on April 30, 2036. He may choose to exercise them any time before that date, paying the $424.45 per share exercise price to receive Vertex common stock directly.

Are Michel Lagarde’s Vertex (VRTX) options subject to vesting conditions?

The filing notes that the options are fully vested. This means Lagarde does not need to meet additional service or performance conditions to exercise them, and he can use the options at any time before their April 30, 2036 expiration.